header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

057 THE USE OF A CALCIUM HYDROXYAPATITE ANTIBIOTIC CARRIER (PEROSSAL*) AS A SPACER IN TWO-STAGE REVISION INFECTED ARTHROPLASTY



Abstract

Two-stage revision procedure is the gold standard in management of periprosthetic infections. Cement spacers have long been used to preserve the space created during resection procedure and to release antiobiotics within the created dead space. However, the problems related to cement as an antibiotic carrier are well recognised (thermal necrosis, random porosity, unspecified antibiotic delivery rate).

To present the concept of using PerOssal as a canal filling spacer and local antibiotic delivery system in two-stage revisions of hip and knee infected arthroplasty.

8 patients (6 females, 2 males) with infected arthroplasty (4 TKRs, 4 THRs) were managed with two-stage revision procedures during the years 2006–2008 (minimum FU: 12 months). Our protocol consisted of:

  1. Preoperative determination of the causative organism

  2. Radical debridement surgery and cement spacer with PerOssal implantation

  3. Appropriate IV antibiotic therapy for 6 weeks, postoperative clinical evaluation and monitoring of inflammation markers

  4. After a six-week antibiotic free interval and inflammation markers normalization second stage surgery took place: Medullary canal reaming, intraoperative cultures, thorough wound irrigation and prostheses implantation

  5. Postoperative antibiotic therapy until culture results; IV antibiotic treatment for 6 more weeks if they were positive.

  6. FU evaluation at 3, 6, 12, and 24 months.

We had 7 cases with eradication of infection, 2 with delayed wound closure, and 1 late recurrence of disease.

We think that PerOssal can offer a very useful additional and genuine support in managing infected joint arthroplasties with so far good clinical results.

Correspondence should be addressed to Anastasia C. Tilentzoglou MD, General Secretary of the Board of Directors of HAOST, 20 A. Fleming Str. (N.Filothei), Gr. 15123 Maroussi, Athens Greece. E-mail: info@eexot.gr